Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.
Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M.
Chakraborty R, et al. Among authors: julian k.
Blood Cancer J. 2024 Aug 12;14(1):137. doi: 10.1038/s41408-024-01114-7.
Blood Cancer J. 2024.
PMID: 39134535
Free PMC article.
No abstract available.